p53, encoded in humans by the TP53 gene, is a central regulator of cellular responses to stress. The protein product acts mainly as a sequence-specific transcription factor that helps preserve genomic stability by directing programs of cell cycle arrest, DNA repair, apoptosis and senescence. Because of this role it has been widely called the "guardian of the genome". Researchers study both the TP53 gene and the p53 protein to understand how cells prevent propagation of damaged DNA.

Key functions

Activated p53 alters gene expression to produce outcomes that limit the spread of mutations. Typical p53-driven effects include:

  • Cell cycle arrest (for example via induction of CDKN1A/p21) to allow DNA repair.
  • Activation of DNA repair pathways that correct damage before replication.
  • Initiation of programmed cell death (apoptosis) when damage is irreparable.
  • Induction of senescence, a durable halt to proliferation in damaged cells.

At the molecular level p53 binds to DNA at specific response elements and regulates gene expression across multiple pathways.

Regulation and activation

In unstressed cells p53 is kept at low abundance by negative regulators such as the ubiquitin ligase MDM2. In response to DNA damage, oncogenic signals, hypoxia or other insults, p53 is stabilized and modified (for example by phosphorylation and acetylation), which increases its activity. Stem cells, including many human embryonic stem cells, maintain relatively low p53 levels to support rapid cell division while protecting genome integrity during development.

History, conservation and mutation in cancer

p53 was identified decades ago as a ~53 kilodalton protein associated with viral oncoproteins and later recognized as a bona fide tumor suppressor. The TP53 gene is highly conserved across animals, and p53-like proteins exist in many organisms. In human tumors TP53 is among the most commonly altered genes: somatic mutations—often missense changes in the DNA-binding domain—disable its protective functions and can act in a dominant-negative manner. Germline TP53 mutations cause hereditary cancer predisposition syndromes, exemplified by Li–Fraumeni syndrome.

Clinical significance and research directions

Loss of p53 function influences prognosis and therapy choices. Restoring p53 activity is a major therapeutic goal; approaches under study include small molecules that reactivate mutant p53, inhibitors of the MDM2–p53 interaction, gene therapy strategies and treatments that exploit p53 deficiency. p53 status is also used as a biomarker in research and, in some settings, in clinical decision-making.

Notable distinctions

  • TP53 refers to the human gene; p53 usually denotes the protein product.
  • p53 belongs to a small family including p63 and p73, which share structural and functional features.
  • Because it integrates many stress signals, p53 has roles beyond classical tumor suppression, including effects on metabolism and aging.

For further introductions and primary resources see gene and protein databases and reviews linked to the TP53 research community: cancer-related resources, historical summaries at guardian of the genome retrospectives, and experimental repositories at DNA-binding data, expression studies and regulatory notes on p53 and TP53.